Table 5.
Baseline characteristics by tertiles of TNFR1 and TNFR2 change in VA NEPHRON-D
| Characteristic | Tertile 1 (n=251) | Tertile 2 (n=252) | Tertile 3 (n=251) | P Value |
|---|---|---|---|---|
| TNFR1 change | ||||
| Range, % change per year | −80% to -0.6% | −0.6%–30% | 30%–335% | — |
| Age, yrs | 64.7±7.5 | 65.1±7.8 | 64.7±7.5 | 0.96 |
| Male | 249 (99%) | 249 (99%) | 250 (100%) | 0.63 |
| Race | ||||
| Black | 54 (22%) | 54 (21%) | 54 (22%) | 0.99 |
| White | 188 (75%) | 189 (75%) | 184 (73%) | |
| Othera | 9 (4%) | 9 (4%) | 13 (5%) | |
| Systolic BP, mmHg | 135±17 | 136±15 | 137±16 | 0.14 |
| Body mass index, kg/m2 | 34.1±6.8 | 34.5±6.3 | 35.1±6.8 | 0.08 |
| Smoking | 50 (20%) | 55 (22%) | 47 (19%) | 0.68 |
| Hemoglobin A1c, % | 7.9±1.3 | 7.8±1.2 | 7.7±1.3 | 0.09 |
| eGFR, ml/min per 1.73 m2 | 56.5±17.9 | 57.2±19.6 | 56.1±19.0 | 0.81 |
| UACR, g/g Cr | 0.68 (0.37–1.37) | 0.76 (0.42, 1.48) | 1.00 (0.51, 2.04) | <0.001 |
| TNFR1 | ||||
| At 0 months, pg/ml | 4815 (3521, 6314) | 3986 (3154, 5529) | 3503 (2446, 4808) | <0.001 |
| At 12 months, pg/ml | 3606 (2718, 4988) | 4541 (3588, 6194) | 5674 (4067, 7798) | <0.001 |
| TNFR2 | ||||
| At 0 months, pg/ml | 11171 (8456, 13755) | 10272 (7942, 13453) | 10143 (7675, 12915) | 0.06 |
| Change, % change per year | −6.68±19.00 | 5.24±19.47 | 23.76±32.78 | <0.001 |
| Randomized group | ||||
| Losartan | 137 (55%) | 124 (49%) | 117 (47%) | 0.19 |
| Losartan + Lisinopril | 114 (45%) | 128 (51%) | 134 (53%) | |
| Tertile 1 (n=251) | Tertile 2 (n=252) | Tertile 3 (n=251) | P value | |
| TNFR2 change | ||||
| Range, % change per year | −84% to -3.8% | −3.8%–14.3% | 14.3%–196% | — |
| Age, years | 64.9±7.5 | 64.6±7.3 | 64.9±7.9 | 0.99 |
| Male | 248 (99%) | 252 (100%) | 248 (99%) | 0.99 |
| Race | ||||
| Black | 50 (20%) | 57 (23%) | 55 (22%) | 0.75 |
| White | 191 (76%) | 182 (72%) | 188 (75%) | |
| Othera | 10 (4%) | 13 (5%) | 8 (3%) | |
| Systolic BP, mmHg | 135±16 | 136±15 | 137±16 | 0.10 |
| Body mass index, kg/m2 | 33.9±6.6 | 34.3±6.4 | 35.5±6.9 | 0.01 |
| Smoking | 54 (22%) | 52 (21%) | 46 (18%) | 0.66 |
| Hemoglobin A1c, % | 7.8±1.3 | 7.7±1.3 | 7.8±1.3 | 0.80 |
| eGFR, ml/min per 1.73 m2 | 55.0±17.5 | 58.5±19.4 | 56.4±19.4 | 0.41 |
| UACR, g/g Cr | 0.66 (0.34, 1.29) | 0.76 (0.46, 1.51) | 1.02 (0.51, 2.20) | <0.001 |
| TNFR1 | ||||
| At 0 months, pg/ml | 4483 (3349, 6006) | 3740 (2908, 5153) | 4086 (3025, 5391) | 0.01 |
| Change, % change per year | −3.14±33.37 | 17.00±35.64 | 50.49±57.35 | <0.001 |
| TNFR2 | ||||
| At 0 months, pg/ml | 11218 (8792, 14347) | 9703 (7648, 12662) | 10273 (7944, 13249) | 0.01 |
| At 12 months, pg/ml | 9108 (7138, 12034) | 10235 (8046, 13319) | 13201 (10239, 18205) | <0.001 |
| Randomized group | ||||
| Losartan | 131 (52%) | 125 (50%) | 122 (49%) | 0.71 |
| Losartan + lisinopril | 120 (48%) | 127 (50%) | 129 (51%) | |
Data presented as mean±SD, number (%), or median (interquartile range). P values presented are for trend. For UACR, P value was determined from natural-log transformed value. Data not available for hemoglobin A1c in seven participants.
a
Other defined as American Indian or Alaska Native, Asian, or Native Hawaiian or Other Pacific Islander.